The Joint United Nations Programme on HIV/AIDS, in conjunction with the Nigerian private sector, is planning to build an antiretroviral manufacturing plant in the North East of Nigeria.
According to a statement, the financial involvement of local and international pharmaceutical companies, National Medicines Regulatory Authorities and multilateral organisations would be assured.
The statement also announced that the Executive Director, UNAIDS and Under-Secretary-General, United Nations, Mr. Michel Sidibé, would be visiting Nigeria from February 7 to 10 to share the 2016-2021 UNAIDS’ strategy with the Buhari government.
The visit would also enable him to get the government’s feedback on how to roll out the strategy and fast track the response to end AIDS by 2030 in Nigeria.
The statement said the UNAIDS head would also discuss the global financial environment and its impact on funding for AIDS and the need for more sustained domestic funding for the Nigerian AIDS response.
It said there would be an opportunity to organise a fund-raising event to mobilise resources for UNAIDS from the Nigerian private sector under the leadership of former President Olusegun Obasanjo and in partnership with the Dangote Foundation and others.
According to the statement, Africa imported 98 percent of its antiretroviral medicines and two manufacturers dominate 71 percent of the African market. This represents a significant risk as African countries look to scale up supplies of antiretroviral medicines, but it also provides an incentive to build domestic pharmaceutical manufacturing capacity and deliver economic dividends for the region.
“Nigeria has the second largest HIV/AIDS epidemic in the world after South Africa. There is a 3.2 percent HIV prevalence in the general population and 3.4 million of its people living with HIV, with almost all its antiretroviral medication coming from outside the country.
“To address these challenges, countries across Africa need to scale up local pharmaceutical production and meet internationally acceptable standards of quality and safety. However, until local production satisfies demand, countries also need to improve their procurement of medicines and related commodities in order to achieve sustainable pricing and stable supplies.”
Sidibé was quoted as saying African leaders had embraced UNAIDS’ fast-track targets for ending AIDS as a public health threat by 2030.
He said this would mean “90 percent of people living with HIV knowing their HIV status, 90 percent of people who know their status receiving treatment and 90 percent of people on HIV treatment having a suppressed viral load so their immune system remains strong and they are no longer infectious.”
According to the statement, after reviewing current procurement practices and shared insights into lowering procurement costs for critical essential medicines and diagnostics, UNAIDS will explore options for further cost reductions through regional pooled procurement, and ways that local industry can be developed in the long term through expanded markets and economies of scale within the West African sub-region.
It said UNAIDS would help facilitate the establishment of clear priorities for improving the security of HIV and related medicines and diagnostics supplies in Africa, drawing on lessons and successes from continental HIV, TB and malaria responses, the experience of achieving cost reductions for viral load tests, and the gaps and needs as exemplified by the recent Ebola outbreaks.
“Lessons learnt from HIV/AIDS could be usefully harnessed to enhanced primary health care and even Lassa Fever and the Zika Virus phenomenon,” it said.